Detalhe da pesquisa
1.
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
Lancet
; 401(10372): 204-214, 2023 Jan 21.
Artigo
Inglês
| MEDLINE | ID: mdl-36509097
2.
Bimekizumab versus Adalimumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 130-141, 2021 07 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33891379
3.
Bimekizumab versus Secukinumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 142-152, 2021 07 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33891380
4.
Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
Allergy
; 2024 Apr 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38563683
5.
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape.
Br J Dermatol
; 190(2): 149-162, 2024 Jan 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37715694
6.
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Lancet
; 400(10348): 273-282, 2022 07 23.
Artigo
Inglês
| MEDLINE | ID: mdl-35871814
7.
Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW study.
Exp Dermatol
; 32(10): 1834-1847, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37272375
8.
Autologous Th2-polarized lymphocytes induce atopic dermatitis lesions in non-atopic human skin xenotransplants.
Allergy
; 78(6): 1538-1553, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36597714
9.
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
Br J Dermatol
; 188(2): 208-217, 2023 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36763879
10.
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Br J Dermatol
; 188(2): 198-207, 2023 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36763857
11.
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
J Eur Acad Dermatol Venereol
; 37(10): 2056-2066, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37335885
12.
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
J Allergy Clin Immunol
; 149(3): 977-987.e14, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34403658
13.
Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment.
Int J Mol Sci
; 24(2)2023 Jan 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36674793
14.
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
Lancet
; 397(10284): 1564-1575, 2021 04 24.
Artigo
Inglês
| MEDLINE | ID: mdl-33894834
15.
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 397(10290): 2169-2181, 2021 06 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34023009
16.
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Lancet
; 397(10273): 475-486, 2021 02 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33549192
17.
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Lancet
; 397(10273): 487-498, 2021 02 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33549193
18.
The hair follicle-psoriasis axis: Shared regulatory mechanisms and therapeutic targets.
Exp Dermatol
; 31(3): 266-279, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34587317
19.
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Br J Dermatol
; 186(6): 942-954, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34981829
20.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.
Br J Dermatol
; 187(4): 531-538, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35442530